Literature DB >> 12018908

Gliclazide-induced acute hepatitis with hypersensitivity features.

Shivakumar Chitturi1, Vu Le, James Kench, Christopher Loh, Jacob George.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12018908     DOI： 10.1023/a:1015002526879

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.487


× No keyword cloud information.
  13 in total

1.  Gliclazide-induced acute hepatitis.

Authors:  S P Dourakis; E Tzemanakis; C Sinani; G Kafiri; S J Hadziyannis
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-01       Impact factor: 2.566

2.  Eosinophilic pleural effusion due to gliclazide.

Authors:  N Tzanakis; D Bouros; N Siafakas
Journal:  Respir Med       Date:  2000-01       Impact factor: 3.415

Review 3.  Drug-induced cholestasis: pathogenesis and clinical features.

Authors:  P D King; B L Blitzer
Journal:  Semin Liver Dis       Date:  1990-11       Impact factor: 6.115

4.  Glibenclamide-induced cholestasis.

Authors:  V N Tholakanahalli; A Potti; M F Heyworth
Journal:  West J Med       Date:  1998-04

5.  Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.

Authors:  A C Desfaits; O Serri; G Renier
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

6.  Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy.

Authors:  B F Clarke; I W Campbell; D J Ewing; G W Beveridge; M K MacDonald
Journal:  Diabetes       Date:  1974-09       Impact factor: 9.461

7.  Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

Authors:  S H Caldwell; D H Oelsner; J C Iezzoni; E E Hespenheide; E H Battle; C J Driscoll
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

8.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

9.  Glyburide-induced hepatitis.

Authors:  R C Goodman; P J Dean; A Radparvar; A E Kitabchi
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

Review 10.  Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

Authors:  B Holmes; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546
View more
  3 in total

Review 1.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

2.  Alleviation of cisplatin-induced hepatotoxicity by gliclazide: Involvement of oxidative stress and caspase-3 activity.

Authors:  Fatemeh Taghizadeh; Seyed Jalal Hosseinimehr; Mehryar Zargari; Abbasali Karimpour Malekshah; Mansoureh Mirzaei; Fereshteh Talebpour Amiri
Journal:  Pharmacol Res Perspect       Date:  2021-05

3.  Clinical applications of drug desensitization in the Asia-Pacific region.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2011-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.